Meeting
2022 ASCO Annual Meeting
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Authors
Michael Weller
Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
Michael Weller , Felix Boakye Oppong , Maureen Vanlancker , Roger Stupp , Louis B. Nabors , Olivier L. Chinot , Wolfgang Wick , Matthias Preusser , Thierry Gorlia , Emilie Le Rhun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2055)
DOI
10.1200/JCO.2022.40.16_suppl.2055
Abstract #
2055
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comparison of survival outcomes of patients with newly diagnosed glioblastoma treated with standard chemoradiation in and outside of clinical trials.
First Author: Rifaquat Rahman
Poster
2013 ASCO Annual Meeting
The Stupp regimen preceded by early post-surgery temozolomide versus the Stupp regimen alone in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM).
First Author: LF Zhou
Poster
2012 ASCO Annual Meeting
A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation.
First Author: Elma S. Hawkins
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland